Last reviewed · How we verify
Maxigesic
Maxigesic is a Small molecule drug developed by Yonsei University. It is currently in Phase 1 development.
Maxigesic is a combination of acetaminophen and ibuprofen, as indicated by its listing as an intervention on ClinicalTrials.gov. It has been studied for various conditions, including postoperative pain, opioid use, and breast cancer, and has been tested in clinical trials such as NCT06479122, which compared its efficacy to acetaminophen alone after a cesarean section.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Maxigesic |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement (NA)
- Preemptive and Preventive Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostatectomy (NA)
- Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients (PHASE4)
- Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (NA)
- Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section (PHASE4)
- Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
- Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination on Postoperative Opioid Consumption (NA)
- Maxigesic® IV Phase 3 Exposure Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maxigesic CI brief — competitive landscape report
- Maxigesic updates RSS · CI watch RSS
- Yonsei University portfolio CI
Frequently asked questions about Maxigesic
What is Maxigesic?
Who makes Maxigesic?
What development phase is Maxigesic in?
Related
- Manufacturer: Yonsei University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing